

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

ATTORNEY DOCKET NO: CXU-407

In re Application of: Scott et al.)
 Serial No: 10/817,423)
 Filed: April 2, 2004)
 Confirmation No: 1563)
 Title: Polypeptides Displaying Binding Affinity for $\alpha\beta 1$)
 Integrin Receptor and $\alpha\beta 4$ Integrin Receptor)

Group Art Unit: 1644
 Examiner: M. Haddad
 Our Client ID: 22827
 Our Account No: 04-1403



Iprius

Commissioner for Patents
 U.S. Patent and Trademark Office
 Post Office Box 1450
 Alexandria, VA 22313-1450

AMENDMENT

This is a response/amendment/letter in the above-identified application and includes the herewith attachment of same date and subject which is incorporated hereinto by reference and the signature below is to be treated as the signature to the attachment in absence of a signature thereto.

Fee requirements (if any) have been calculated as shown below:

Claims remaining after amendment	Highest number previously paid for	Present Extra	Additional Fee
Total Effective Claims 21 minus 42 = 0		X \$50 =	\$.00
Independent Claims 4 minus 5 = 0		x \$200 =	\$.00
If amendment enters <u>proper</u> multiple dependent claim(s) into this application for <u>first</u> time, add \$290.00 (per application)			\$.00
Since Official Action set an <u>original</u> due date of <u>November 12, 2005</u> , PETITION is hereby made for an extension to cover the date this response is filed for which the requisite fee is enclosed (1 month \$120; 2 months \$450; 3 months \$1020; 4 months \$1590, 5 months \$2,160)			\$.00
If Terminal Disclaimer enclosed, add Rule 20(d) Official Fee (\$110.00)			\$.00
SUBTOTAL:			\$.00
If "small entity" verified statement filed [] previously, [] herewith, enter one-half (1/2) of subtotal and <u>subtract</u>			\$.00
TOTAL:			\$.00
Other: <u>Information Disclosure Statement</u>			\$ 180.00
TOTAL FEE ENCLOSED:			\$ 180.00

The Commissioner is hereby authorized to charge any fee specifically authorized hereafter, or any fees in addition to the fee(s) filed, or asserted to be filed, or which should have been filed herewith or concerning any paper filed hereafter, and which may be required under Rules 16-18 (deficiency only) now or hereafter relative to this application and the resulting official document under Rule 20, or credit any overpayment, to our Account No. shown in the heading hereof for which purpose a duplicate copy of this sheet is attached. This statement does not authorize charge of the issue fee in this case.

ADDRESS:
 Post Office Box 1449
 Greenville, SC 29602 USA
 Customer ID No.: 22827
 Telephone: 864-271-1592
 Facsimile: 864-233-7342

DORITY & MANNING
ATTORNEYS AT LAW, P.A.

By: Christina L. Mangelsen, Patent Agent Reg. No: 50,244
 Date: November 9, 2005
 Signature: *Christina L. Mangelsen*

I hereby certify that this correspondence and any referenced attachment and fee are being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, U.S. Patent and Trademark Office, Post Office Box 1450, Alexandria, VA 22313-1450, on November 9, 2005.

Sandra S. Perkins

(Typed or printed name of person mailing paper or fee)

Sandra S. Perkins
 (Signature of person mailing paper or fee)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of Scott et al.

Serial No: 10/817,423

Filed: April 2, 2004

For: Polypeptides Displaying Binding
Affinity for $\alpha 6\beta 1$ Integrin Receptor
and $\alpha 6\beta 4$ Integrin Receptor



) Examiner: M. Haddad

) Art Unit: 1644

) Confirmation No: 1563

) Deposit Account No: 04-1403

) Customer No: 22827
)

AMENDMENT

Honorable Commissioner of Patents and Trademarks
U.S. Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

In response to the Office Action dated August 12, 2005, please find attached hereto:

Amendments to the Specification beginning on page 2 of this paper,
Amendments to the Claims beginning on page 4 of this paper, and
Remarks, beginning on page 7 of this paper.

11/15/2005 HTECKLU1 00000006 10817423

01 FC:1806

180.00 OP